Acquired tumor resistance to antiangiogenic therapy: Mechanisms at a glance

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis by supplying oxygen and nutrients.
• Antiangiogenic therapies, often targeting the vascular endothelial growth factor (VEGF) pathway, aim to inhibit tumor growth by starving cancer cells.
• While preclinical studies show promise, clinical efficacy of antiangiogenic therapy is often limited by the development of resistance.

Purpose of the Study:

• To review novel mechanisms of evasive resistance to antiangiogenic therapies.
• To identify cancer types that adapt to VEGF inhibition.
• To understand how tumors overcome antiangiogenic strategies through adaptive mechanisms.

Main Methods:

• Literature review of preclinical and clinical studies on antiangiogenic therapy resistance.
• Analysis of molecular pathways involved in tumor angiogenesis and resistance.
• Identification of compensatory angiogenic mechanisms activated during VEGF blockade.

Main Results:

• Tumor resistance to antiangiogenic therapy arises from activation of alternative angiogenic pathways.
• VEGF inhibition can trigger compensatory mechanisms that sustain tumor angiogenesis.
• These adaptive mechanisms lead to tumor growth restoration, invasion, metastasis, and recurrence.

Conclusions:

• Tumor adaptation and activation of compensatory angiogenic pathways are key mechanisms of resistance to antiangiogenic therapy.
• Understanding these evasive resistance mechanisms is crucial for developing more effective cancer treatments.
• Targeting alternative pathways may overcome resistance and improve outcomes in various cancer types.